期刊
EUROPACE
卷 24, 期 4, 页码 538-551出版社
OXFORD UNIV PRESS
DOI: 10.1093/europace/euab274
关键词
Antiarrhythmic drugs; Catheter ablation; Implantable cardioverter-defibrillator; Ischaemic cardiomyopathy; Sudden cardiac death; Ventricular tachycardia
Sudden cardiac death caused by ischaemic cardiomyopathy is a major concern, with implantation of cardioverter-defibrillator being a common preventive measure. Catheter ablation has been shown to reduce ventricular tachycardia recurrences in patients with ICM, and emerging concepts like sympathetic cardiac denervation hold promise for expanding therapeutic options in therapy-refractory VT. Further research is needed to investigate the potential benefits of these novel strategies for improving patient outcomes.
Worldwide, similar to 4 million people die from sudden cardiac death every year caused in more than half of the cases by ischaemic cardiomyopathy (ICM). Prevention of sudden cardiac death after myocardial infarction by implantation of a cardioverter-defibrillator (ICD) is the most common, even though not curative, therapy to date. Optimized ICD programming should be strived for in order to decrease the incidence of ICD interventions. Catheter ablation reduces the recurrence of ventricular tachycardias (VTs) and is an important adjunct to sole ICD-based treatment or pharmacological antiarrhythmic therapy in patients with ICM, as conclusively demonstrated by seven randomized controlled trials (RCTs) in the last two decades. However, none of the conducted trials was powered to reveal a survival benefit for ablated patients as compared to controls. Whereas thorough consideration of an early approach is necessary following two recent RCTs (PAUSE-SCD, BERLIN VT), catheter ablation is particularly recommended in patients with recurrent VT after ICD therapy. In this context, novel, pathophysiologically driven ablation strategies referring to deep morphological and functional substrate phenotyping based on high-resolution mapping and three-dimensional visualization of scars appear promising. Emerging concepts like sympathetic cardiac denervation as well as radioablation might expand the therapeutical armamentarium especially in patients with therapy-refractory VT. Randomized controlled trials are warranted and on the way to investigate how these translate into improved patient outcome. This review summarizes therapeutic strategies currently available for the prevention of VT recurrences, the optimal timing of applicability, and highlights future perspectives after a PAUSE in BERLIN.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据